Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 7/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11579276 | 0.78 | ALDH1A1 (0.67) | ALDH1A1HIF1AVCAM1ATMTDP1 | |
| SCHEMBL29462663 | 0.78 | ATM (0.69) | ALDH1A1HIF1AVCAM1ATMTDP1 | |
| SCHEMBL1970698 | 0.78 | CASP6 (0.39) | ALDH1A1HIF1AATMTDP1LMNA | |
| SCHEMBL102780 | 0.78 | ATM (0.69) | ALDH1A1HIF1AVCAM1ATMTDP1 | |
| SCHEMBL29349904 | 0.77 | ALDH1A1 (1.00) | ALDH1A1HIF1AVCAM1ATMTDP1 | |
| SCHEMBL29580152 | 0.77 | ALDH1A1 (0.64) | ALDH1A1HIF1AVCAM1ATMTDP1 | |
| SCHEMBL306375 | 0.77 | ALDH1A1 (0.64) | ALDH1A1HIF1AVCAM1ATMTDP1 | |
| SCHEMBL27715742 | 0.77 | ALDH1A1 (1.00) | ALDH1A1HIF1AVCAM1ATMTDP1 | |
| Hydrogen Sulfide SCHEMBL21810723 | 0.77 | ATM (0.67) | ALDH1A1HIF1AVCAM1ATMTDP1 | |
| SCHEMBL35276 | 0.77 | ALDH1A1 (1.00) | ALDH1A1HIF1AVCAM1ATMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11969425-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | INVENTISBIO LLC (US) | 2024-04-30 | — | — | US | disclosed |
| CN-113896685-B | Indoleamine-2, 3-dioxygenase (IDO) inhibitors | 益方生物科技(上海)股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2023-10-26 | — | — | US | disclosed |
| EP-3414224-B1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-02-24 | — | — | US | disclosed |
| CN-113896685-A | Indoleamine-2, 3-dioxygenase (IDO) inhibitors | 益方生物科技(上海)股份有限公司 | 2022-01-07 | — | — | CN | disclosed |
| US-10980807-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | INVENTISBIO LLC (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200046697-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2020-02-13 | — | — | US | disclosed |
| EP-3414224-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | Inventisbio Inc. (KY) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139414-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO INC. (KY) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139414-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO INC. (KY) | 2017-08-17 | — | — | WO | disclosed |
| EP-2491785-A1 | Method and compositions for treating HIV infections | Purdue Research Foundation (US) | 2012-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | ALDH1A1 801/4885HIF1A 2346/4885VCAM1 2572/4885 |
| US-11969425-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | IDO1, IDO2, INMT | ALDH1A1 801/4885HIF1A 2346/4885VCAM1 2572/4885 |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | ALDH1A1 801/4885HIF1A 2346/4885VCAM1 2572/4885 |
| US-20200046697-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | ALDH1A1 801/4885HIF1A 2346/4885VCAM1 2572/4885 |
| US-10980807-B2 | Inhibitor of indoleamine-2,3-dioxygenase (IDO) | IDO1, IDO2, INMT | ALDH1A1 801/4885HIF1A 2346/4885VCAM1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.